Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598338 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL15569994 | 0.98 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9254635 | 0.85 | KDM4E (0.53) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL28248149 | 0.84 | KMT2A (0.51) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL188296 | 0.84 | MEN1 (0.65) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL27938205 | 0.83 | KDM4E (0.51) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL8082335 | 0.83 | MEN1 (0.47) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13254933 | 0.82 | CYP3A4 (0.48) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1706450 | 0.82 | MMP2 (0.60) | SMN1; SMN2MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL25078318 | 0.80 | MEN1 (0.44) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101250135-A | Synthetic method of 2-amino-N, N-dimethylbenzamide | YANCHENG LVYE CHEMICAL INDUSTR (CN) | 2008-08-27 | — | — | CN | claimed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022214008-A1 | HIGHLY ACTIVE HPK1 KINASE INHIBITOR | 杭州阿诺生物医药科技有限公司 | 2022-10-13 | — | — | WO | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3994133-A1 | HPK1 INHIBITORS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2022-05-11 | — | — | EP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| EP-3325475-B1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-10308643-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| WO-1998040361-A1 | AMINOSULFONYLUREAS WITH HERBICIDAL ACTIVITY | ISAGRO RICERCA S.R.L. (IT) | 1998-09-17 | — | — | WO | disclosed |
| US-5688795-A | URINARY TRACTS OBSTRUCTION | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| EP-0317859-B1 | AZO DYES CONTAINING POLYETHYLENIMINE | BASF Aktiengesellschaft (DE) | 1991-11-27 | — | — | EP | disclosed |
| US-4962190-A | PRINTING, DYEING CELLULOSE CONTAINING MATERIAL | BASF AKTIENGESELLSCHAFT (DE) | 1990-10-09 | — | — | US | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| EP-0084853-B1 | PROCESS FOR THE PREPARATION OF 1,8-NAPHTHOLACTAM COMPOUNDS | CIBA-GEIGY AG (CH) | 1986-11-12 | — | — | EP | disclosed |
| US-4515963-A | AMIDATIUON OF NAPHTHOLACTONE | CIBA GEIGY AG (CH) | 1985-05-07 | — | — | US | disclosed |
| EP-0084853-A1 | Process for the preparation of 1,8-naphtholactam compounds | CIBA-GEIGY AG (CH) | 1983-08-03 | — | — | EP | disclosed |
| US-4163059-A | Pesticidally active 4,5-dichloro-3-substituted-phenylimino-1,2-dithiolenes | BAYER AKTIENGESELLSCHAFT (DE) | 1979-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | SMN1; SMN2 3906/4885MEN1 3442/4885KMT2A 1353/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | SMN1; SMN2 3998/4885MEN1 1442/4885KMT2A 2256/4885 |
| US-10308643-B2 | Heterocyclic compound | HDAC1, HDAC11, HDAC5 | SMN1; SMN2 38/4885MEN1 2720/4885KMT2A 47/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | SMN1; SMN2 986/4885MEN1 636/4885KMT2A 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.